Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
Elaine S TanBassel El-RayesPublished in: Journal of gastrointestinal cancer (2019)
Various preclinical and early clinical studies have shown that immunotherapy, especially checkpoint inhibitors, in PDAC may be efficacious as part of a multi-modal treatment, in combination with other therapies that target these resistance mechanisms. Several clinical trials are ongoing to explore this concept further.